Page 156 - Read Online

Li et al. J Cancer Metastasis Treat 2020;6:14 I http://dx.doi.org/10.20517/2394-4722.2020.27 Page 17 of 17

105. Takahashi M, Cooper GM. Ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol 1987;7:1378-
85.
106. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002;3:383-94.
107. Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer 2014;14:173-86.
108. Kohno T, Tsuta K, Tsuchihara K, Nakaoku T, Yoh K, et al. RET fusion gene: translation to personalized lung cancer therapy. Cancer Sci
2013;104:1396-400.
109. de Graaff E, Srinivas S, Kilkenny C, D’Agati V, Mankoo BS, et al. Differential activities of the RET tyrosine kinase receptor isoforms
during mammalian embryogenesis. Genes Dev 2001;15:2433-44.
110. Chi X, Michos O, Shakya R, Riccio P, Enomoto H, et al. Ret-dependent cell rearrangements in the Wolffian duct epithelium initiate
ureteric bud morphogenesis. Dev Cell 2009;17:199-209.
111. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, et al. PTC is a novel rearranged form of the ret proto-oncogene and is
frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-63.
112. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292-306.
113. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from
whole-genome and transcriptome sequencing. Genome Res 2012;22:436-45.
114. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
115. Tsuta K, Kohno T, Yoshida A, Shimada Y, Asamura H, et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and
molecular analysis. Br J Cancer 2014;110:1571-8.
116. Wang R, Hu H, Pan Y, Li Y, Ye T, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung
cancer. J Clin Oncol 2012;30:4352-9.
117. Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, et al. RET aberrations in diverse cancers: next-generation sequencing of 4,871
patients. Clin Cancer Res 2017;23:1988-97.
118. Chao BH, Briesewitz R, Villalona-Calero MA. RET fusion genes in non-small-cell lung cancer. J Clin Oncol 2012;30:4439-41.
119. Ferrara R, Auger N, Auclin E, Besse B. Clinical and translational implications of RET rearrangements in non-small cell lung cancer. J
Thorac Oncol 2018;13:27-45.
120. Plenker D, Riedel M, Bragelmann J, Dammert MA, Chauhan R, et al. Drugging the catalytically inactive state of RET kinase in RET-
rearranged tumors. Sci Transl Med 2017;9.
121. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun 2014;5:4846.
122. Le Rolle AF, Klempner SJ, Garrett CR, Seery T, Sanford EM, et al. Identification and characterization of RET fusions in advanced
colorectal cancer. Oncotarget 2015;6:28929-37.
123. Li AY, McCusker MG, Russo A, Scilla KA, Gittens A, et al. Cancer Treat Rev 2019;81:101911.
124. Li GG, Somwar R, Joseph J, Smith RS, Hayashi T, et al. Antitumor activity of RXDX-105 in multiple cancer types with RET
rearrangements or mutations. Clin Cancer Res 2017;23:2981-90.
125. Matsubara D, Kanai Y, Ishikawa S, Ohara S, Yoshimoto T, et al. Identification of CCDC6-RET fusion in the human lung adenocarcinoma
cell line, LC-2/ad. J Thorac Oncol 2012;7:1872-6.
126. Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, et al. Cancer Discov 2018;8:836-49.
127. Guo R, Schreyer M, Chang JC, Rothenberg SM, Henry D, et al. Response to selective RET inhibition with LOXO-292 in a patient with
RET fusion-positive lung cancer with leptomeningeal metastases. JCO Precis Oncol 2019;3.
128. Drilon A, Oxnard G, Wirth L, Besse B, Gautschi O, et al. PL02.08 registrational results of LIBRETTO-001: a phase 1/2 trial of LOXO-
292 in patients with RET fusion-positive lung cancers. J Thorac Oncol 2019;14:S6-7.
129. Gainor JF, Lee DH, Curigliano G, Doebele RC, Kim DW, et al. Clinical activity and tolerability of BLU-667, a highly potent and selective
RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). J Clin Oncol 2019;37:9008.
130. Lacombe D, Burock S, Bogaerts J, Schoeffski P, Golfinopoulos V, et al. The dream and reality of histology agnostic cancer clinical trials.
Mol Oncol 2014;8:1057-63.
131. Chu P, Batson S, Hodgson M, Mitchell CR, Steenrod A. Systematic review of neurotrophic tropomyosin-related kinase inhibition as a
tumor-agnostic management strategy. Future Oncol 2020;16:61-74.
132. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
133. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med 2011;364:2507-16.
134. Kim YS, Kim JS, Bae JS, Park WC. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma. World J Surg
Oncol 2013;11:99.
135. Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated
colorectal cancer. J Clin Oncol 2015;33:4032-8.
136. Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, Hollebecque A, et al. Molecular targeted therapy of BRAF-mutant colorectal
cancer. Ther Adv Med Oncol 2019;11:1758835919856494.